Anti-IGF-IR antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-8945871-B2
Application number	US-201313745142-A
Country	US
Kind code	B2
Filing date	Jan 18, 2013
Priority date	Jul 22, 2005
Publication date	Feb 3, 2015
Grant date	Feb 3, 2015

Abstract

The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR). The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR, stimulated either by IGF1 and/or IGF2, or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or the IGF-I/Insulin hybrid receptor.

First claim

The invention claimed is:

1. An isolated nucleic acid, selected from the group consisting of:
a) a nucleic acid coding for an antibody that specifically binds insulin-like growth factor 1 receptor (IGF-1R), or an antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof comprises: (i) a heavy chain comprising three CDRs of sequence SEQ ID NOS: 2, 4 and 6, and (ii) a light chain comprising three CDRs of sequence SEQ ID NOS: 1, 3 and 5;
b) a nuclei…

Assignees

• Pf Medicament

Inventors

• Goetsch Liliane
• Corvaia Nathalie

Classifications

• A61P43/00

  Human Necessities · mapped topic

• A61P9/10

  Human Necessities · mapped topic

• A61P35/00

  Human Necessities · mapped topic

• C07K16/2863 Primary

  Chemistry & Metallurgy · mapped topic

• C07K2317/24

  Chemistry & Metallurgy · mapped topic